eligibility_summary
Eligible: 18–70, confirmed CRC with measurable disease, progressed after 1st‑line (≥2 wks off), ECOG 0–1, life expectancy ≥3 mo, adequate organ function, negative pregnancy test/contraception. Exclude: uncontrolled brain mets, need other cancer therapy, recent steroids, immunotherapy, or trial, serious CV disease/arrhythmia or uncontrolled HTN, bleeding risk or recent thrombosis, active infection incl hepatitis/HIV/TB, pregnancy/breastfeeding, severe allergy, substance abuse, unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: personalized tumor neoantigen-loaded dendritic cell (DC) vaccine plus conventional second-line therapy (physician’s choice of chemotherapy, targeted agents, and/or a PD-1 inhibitor). Mechanisms: DC vaccine (autologous cellular immunotherapy) uses ex vivo–generated DCs pulsed with patient-specific neoantigen peptides (from WES/RNA-seq) to present antigens via HLA I/II, provide co-stimulation (CD80/86) and cytokines, and prime/expand neoantigen-specific CD8+ cytotoxic and CD4+ helper T cells for tumor killing. PD-1 inhibitor (monoclonal antibody checkpoint blocker) restores exhausted T-cell function by blocking PD-1/PD-L1 signaling. Chemotherapy (cytotoxic) reduces tumor burden and can increase antigen release/immunogenic cell death, targeted drugs act on oncogenic pathways per CRC standard. Targets/cells: administered DCs, patient CD8+/CD4+ T cells, tumor cells bearing neoantigens, PD-1/PD-L1 axis, antigen presentation/TCR signaling.